Trading was heavy with 8,143K shares changing hands by the end of trading on Tuesday. Shares saw a steep increase in trading volume of 276.65% over the normal average daily volume.
A few notable investment firms have updated their holdings. As of the end of the quarter Citadel Advisors LLC had bought a total of 19,199 shares growing its stake by 99.5%. The value of the investment in NWBO went from $11,000 to $123,000 a change of 1,018.2% for the reporting period.
The company is up by 9.17% since yesterday’s close of 0.229. The company’s P/E ratio is N/A and market capitalization is 77.55M. In the last earnings report the EPS was $-0.45 with 315.86M shares now outstanding.
Northwest Biotherapeutics, Inc., launched on July 29, 1998, is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Business’s lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct..